Recent studies have converged on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopamine communication. While GCGR stimulators are widely employed for treating type 2 diabetes mellitus, their potential effects on reward circuits, specifically governed by dopaminergic systems, are attracting significan